Loading news...
ITM Power PLC (AIM:ITM) said it has secured two engineering contracts with a combined capacity of 70 MW, sending its shares up 6% to 66.3p. The first award is a basic design engineering package for an industrial customer in Australia, deploying multiple units of its Neptune V containerised green hydrogen plant.
ITM Power PLC (AIM:ITM) has been selected by Stablegrid Group to supply technology for two energy infrastructure projects in Germany with a combined capacity of 710 MW. The projects will use electrolysers to support grid balancing by converting surplus renewable power into hydrogen stored in underground caverns.
VanEck Intermediate Muni ETF tracks intermediate-term, investment-grade municipal bonds, offering tax-free income but only middling returns for the risk taken. ITM's low fees (0.18%) and index-tracking approach provide diversification and lower interest rate risk but limit income potential compared to more selective strategies. Tax-equivalent yields make ITM best suited for investors in higher tax brackets; those below a 24% marginal rate may find better after-tax returns elsewhere.
Garching / Munich, Germany, October 17, 2025 - ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that post hoc subgroup analyses data from its recent Phase 3 COMPETE trial will be presented in an oral presentation at the 2025 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium held from October 22 - October 25, 2025 in Austin, Texas.
Garching / Munich, Germany, October 13, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the appointment of Annette Breunig as Chief People Officer (CPO). Ms. Breunig brings over 25 years of HR leadership experience at international pharmaceutical, manufacturing and technology companies, including at Siemens AG (FRA: SIE) and Sanofi (Nasdaq: SNY). At ITM, Ms. Breunig will lead the HR team in shaping strategies that unify the organization to achieve both team and business growth objectives while empowering employees, strengthening company culture and attracting top talent. “Annette's dedication to supporting top-performing teams at global, high-growth companies has created dynamic work environments. As ITM continues scaling its organization to meet the needs of people living with cancer, her leadership will be a great addition,” said Dr. Andrew Cavey, CEO of ITM. “Our people are the core that drive our success. This appointment further strengthens our HR team's ability to elevate employees and ensures that ITM remains a great place to work as we advance our mission to develop innovative radiopharmaceuticals .” As Executive Vice President of People & Culture at Infios Group (formerly Körber Supply Chain Software), Annette led the integration of the company's workforce across 10 countries in Asia, Europe, and the United States into a cohesive and unified global culture. As Vice President of HR at Körber Supply Chain Group and at Körber Pharma she established global HR Teams, developed and implemented the companies' global people strategies, and launched major global culture initiatives. Annette also held global senior leadership and management roles for more than ten years at Siemens AG, where she oversaw strategic and operational HR functions, including the development of systems for hiring and developing best-in-class talent, and the designed compensation strategies and policies. She also worked in senior management HR roles at Aventis, acquired by Sanofi in 2004, developing and implementing benefit plans in the EU, US and Asia. Ms. Breunig is a certified business coach and holds a business degree from the Julius Maximilians University in Wuerzburg, Germany. “ITM's evolution into a global radiopharmaceutical leader is a true growth story, driven by innovation and the passion of its people. I was drawn to ITM's clear purpose, improving outcomes for people with cancer, and I look forward to working with this dynamic team to support its continued growth and global success,” added Annette Breunig, CPO of ITM. About ITM Isotope Technologies Munich SE ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply of medical radioisotopes. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including multiple Phase 3 studies, combining the company's high-quality radioisotopes with a range of targeting molecules. By leveraging our two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life. www.itm-radiopharma.com ITM Contact Corporate Communications Kathleen Noonan/Julia WestermeirPhone: +49 89 329 8986 1500Email: communications@itm-radiopharma.com Investor Relations Ben OrzelekPhone: +49 89 329 8986 1009Email: investors@itm-radiopharma.com
ITM Power PLC (AIM:ITM) shares advanced in Monday morning's deals, after it announced the signing of a Front-End Engineering Design (FEED) contract for a hydrogen project shortlisted in the UK's Hydrogen Allocation Round 2. The FEED will cover multiple 'NEPTUNE V' units, each of which will be a 5MW containerised green hydrogen plant.
Supports Clinical Development of CLR 121225, Actinium-Labeled Compound for the Treatment of Solid Tumors Supports Clinical Development of CLR 121225, Actinium-Labeled Compound for the Treatment of Solid Tumors
ITM Power PLC (AIM:ITM) has signed a supply agreement and binding heads of terms for a long-term services deal with MorGen Energy for the 20MW West Wales Hydrogen project at Milford Haven, UK. The project is part of the UK Government's Hydrogen Allocation Round 1 programme and has secured permits.
ITM Power PLC (AIM:ITM) shares traded up 9% in Tuesday's early deals after announcing contract wins for a pair of projects in the UK. The British technology and engineering small-cap in a statement, said it had been selected as the supplier for two green hydrogen projects in the UK.
Garching / Munich, Germany, May 27, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced a debt financing agreement for up to USD 262.5 million from funds managed by Blue Owl Capital, Inc (“Blue Owl”). The capital will be used to prepare for commercial readiness and potential market launch of the company's lead candidate, n.c.a. 177Lu-edotreotide (also known as ITM-11 or 177Lu-edotreotide). ITM-11 recently met the primary endpoint in the COMPETE Phase 3 study as a potential treatment for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). ITM plans to submit a New Drug Application (NDA) for this asset to the U.S. FDA in 2025. In addition, the company will continue to accelerate the development of its innovative targeted radiopharmaceutical pipeline and the scale-up of Actinium-225 manufacturing through its joint venture, Actineer. Under the terms of the agreement, ITM will receive USD 140 million upon closing and can exercise additional tranches. Further details of the agreement have not been disclosed.
GARCHING / MUNICH, Germany and SYDNEY, May 19, 2025 (GLOBE NEWSWIRE) -- ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Radiopharm Theranostics (ASX:RAD; NASDAQ: RADX “Radiopharm”), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, today announced the signing of a supply agreement that will provide Radiopharm with ITM's medical radioisotope, non-carrier-added Lutetium-177 (n.c.a. 177Lu), to enable its usage in the clinical and potential future commercial development of the 177Lu-based molecules in Radiopharm's development pipeline.
Shares in ITM Power PLC (AIM:ITM) surged 18% in early trading on Monday after the company announced it had been selected to supply more than 300MW of electrolysers for a major green hydrogen project in the Asia-Pacific region. The UK-based clean energy firm said it had signed an agreement with a customer, who has not yet been named, confirming its role in the project, which aims to produce hydrogen for use in power generation and reduce carbon emissions.
Garching / Munich, Germany and VANCOUVER, British Columbia, April 24, 2025 – ITM Isotope Technologies Munich SE (ITM) , a leading radiopharmaceutical biotech company, and Alpha-9 Oncology (Alpha-9) , a clinical-stage biotechnology company advancing a distinctive portfolio of differentiated and highly targeted radiopharmaceuticals, today announced the signing of a supply agreement for Actinium-225 (Ac-225) to support the development of Alpha-9's radiopharmaceutical programs. Under the terms of the agreement, ITM will supply its therapeutic medical radioisotope, Ac-225, produced by ActineerTM Inc. (Actineer), the joint venture between ITM and Canadian Nuclear Laboratories. Actineer is advancing cutting-edge technologies to secure and expand its supply chain and produce industrial-scale quantities of Ac-225 at rapid speed to meet the growing global demand. Further contract details have not been disclosed.
Shares in ITM Power PLC (AIM:ITM) rose 8% to 31.08p on Tuesday after the hydrogen technology group lifted its revenue forecast for the year — a rare upside surprise that analysts say strengthens its recovery story. The Sheffield-based company, which develops electrolyser systems for green hydrogen production, now expects full-year revenue to come in between £25.5m and £26.5m.
ITM Power PLC (AIM:ITM) shares climbed 21% in early trading on Tuesday after the company raised its revenue guidance and reported that it had been cash generative in the second half of the financial year. The hydrogen energy group said it now expects revenue for the year ending 30 April 2025 to reach between £25.5mn and £26.5mn, representing a 30% increase on the midpoint of its previous forecast.
Compare corporate and municipal bonds, including risks, returns, and tax benefits. Learn which bond type fits your investment goals.
Municipal bonds are back to offer compelling risk-adjusted opportunities, but future decisions from Washington can either act as a tailwind or headwind. Municipal bond funds saw net inflows during 2024, first annual inflow since 2021—which was a record year. 2024 was a record year in municipal bond issuance. With attractive yields, the market may start to pay more attention to tax-equivalent yield advantages offered through municipal debt.
Hydrogen has gone off the oil recently as the sector continues to face delays, with financial investment decisions (FIDs) remaining limited. US bank Jefferies still sees potential for certain companies within the industry that are showing varying degrees of resilience and outlook improvements.
Specific to the muni market, perhaps the biggest surprise this year has been new issue supply that is running well ahead of expectations, up roughly 40% from last year. We think this increased summer issuance is likely the result of deals getting pulled forward, as issuers may be cautious about coming to market later in the fall ahead of what is likely to be an uncertain U.S. political climate. While municipal credit quality has already peaked, it is entering this period of moderating economic growth from a position of strength.
ITM Power PLC (AIM:ITM) needs to turn customer interest into order growth but is in the hands of a “lacklustre” green hydrogen market, according to UBS analysts. Analysts from the bank cut the clean technology company's share price target from 65p to 60p on Wednesday as a result, alongside issuing a ‘neutral' rating.